What happens if I overdose Rosuast?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Proper storage of Rosuast:
Store Rosuast at room temperature, between 68 and 77 degrees F (20 to 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Rosuast out of the reach of children and away from pets.
Overdose of Rosuast in details
There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of Rosuast.
However, no specific symptoms of an overdose have been reported.
What should I avoid while taking Rosuast?
Avoid drinking alcohol. It can raise triglyceride levels and may increase your risk of liver damage.
Avoid using antacids without your doctor's advice. Use only the type of antacid your doctor recommends, and do not take it within 2 hours after taking Rosuast. Some antacids can make it harder for your body to absorb Rosuast.
Avoid eating foods that are high in fat or cholesterol. Rosuast will not be as effective in lowering your cholesterol if you do not follow a cholesterol-lowering diet plan.
Rosuast warnings
Skeletal Muscle Effects
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including Rosuast. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
Rosuast should be prescribed with caution in patients with predisposing factors for myopathy (e.g., age ≥ 65 years, inadequately treated hypothyroidism, renal impairment).
The risk of myopathy during treatment with Rosuast may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir. Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors, including Rosuast, coadministered with colchicine, and caution should be exercised when prescribing Rosuast with colchicine.
Rosuast therapy should be discontinued if markedly elevated creatine kinase levels occur or myopathy is diagnosed or suspected. Rosuast therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).
There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.
All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing Rosuast.
Liver Enzyme Abnormalities
It is recommended that liver enzyme tests be performed before the initiation of Rosuast, and if signs or symptoms of liver injury occur.
Increases in serum transaminases [AST (SGOT) or ALT (SGPT)] have been reported with HMG‑CoA reductase inhibitors, including Rosuast. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of jaundice, for which a relationship to Rosuast therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of liver failure or irreversible liver disease in these trials.
In a pooled analysis of placebo-controlled trials, increases in serum transaminases to >3 times the upper limit of normal occurred in 1.1% of patients taking Rosuast versus 0.5% of patients treated with placebo.
There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including Rosuast. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with Rosuast, promptly interrupt therapy. If an alternate etiology is not found, do not restart Rosuast.
Rosuast should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of Rosuast.
Concomitant Coumarin Anticoagulants
Caution should be exercised when anticoagulants are given in conjunction with Rosuast because of its potentiation of the effect of coumarin-type anticoagulants in prolonging the prothrombin time/INR. In patients taking coumarin anticoagulants and Rosuast concomitantly, INR should be determined before starting Rosuast and frequently enough during early therapy to ensure that no significant alteration of INR occurs.
Proteinuria and Hematuria
In the Rosuast clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among Rosuast treated patients. These findings were more frequent in patients taking Rosuast 40 mg, when compared to lower doses of Rosuast or comparator HMG‑CoA reductase inhibitors, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, a dose reduction should be considered for patients on Rosuast therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.
Endocrine Effects
Increases in HbA1c and fasting serum glucose levels have been reported with HMG‑CoA reductase inhibitors, including Rosuast. Based on clinical trial data with Rosuast, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus.
Although clinical studies have shown that Rosuast alone does not reduce basal plasma cortisol concentration or impair adrenal reserve, caution should be exercised if Rosuast is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.
What should I discuss with my healthcare provider before taking Rosuast?
- If you have an allergy to Rosuast or any other part of Rosuast (Rosuast sprinkle capsules).
- If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
- If you have any of these health problems: Active liver disease or a rise in liver enzymes.
- If you are taking gemfibrozil.
- If you are pregnant or may be pregnant. Do not take Rosuast (Rosuast sprinkle capsules) if you are pregnant.
- If you are breast-feeding. Do not breast-feed while you take Rosuast (Rosuast sprinkle capsules).
This is not a list of all drugs or health problems that interact with Rosuast (Rosuast sprinkle capsules).
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Rosuast (Rosuast sprinkle capsules) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Rosuast precautions
Renal and hepatic impairment; severe respiratory failure. Repeated or unexplained muscle aches or pains (myopathy), a personal or family history of muscle problems or a previous history of muscle problems when taking other cholesterol-lowering drugs; regular consumption of large amounts of alcohol; thryoid gland disorders; if taking fibrates to lower cholesterol, drugs used for HIV infection eg, lopinavir, ritonavir; Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).
If the patient has an intolerance to some sugars (lactose or milk sugar), consult doctor before taking Rosuast Sandoz.
In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, the physician will usually carry out a blood test (liver function test) before and during treatment with Rosuast Sandoz.
Effects on the Ability to Drive or Operate Machinery: Most patients can drive a car and operate machinery while using Rosuast Sandoz- it will not affect their ability. However, some people feel dizzy during treatment with Rosuast Sandoz. If dizziness occurs, consult the physician before attempting to drive or use machines.
Use in children: If the patient is <10 years, Rosuast Sandoz should not be given. If the patient is <18 years, Rosuast Sandoz 40 mg is not suitable for use.
Use in the
Elderly: If the patient is >70 years, the physician needs to choose the right starting dose of Rosuast Sandoz that will best suit the patient.
What happens if I miss a dose of Rosuast?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
References
- DailyMed. "ROSUVASTATIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "Rosuvastatin". http://www.drugbank.ca/drugs/DB01098 (accessed September 17, 2018).
- MeSH. "Hydroxymethylglutaryl-CoA Reductase Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
